Impact des toxicités cutanées associées aux thérapies ciblées sur la qualité de vie. Résultats d'une étude pilote longitudinale

Targeted therapies represent a promising option in cancer treatment, which have shown tumor control and patients survival benefits. But these drugs have systemic side effects, in particular frequent and various cutaneous effects. Few data have been published about the impact of these symptoms on patients' quality of life, particularly for psychological and social aspects. That is why we wished to evaluate this impact in order to propose a preventive management and optimize patients' care. Twenty-seven patients participated in both evaluation times of a longitudinal quantitative pilot study. They completed the same set of psychological questionnaires before taking treatment and 30 days after. Patients were mainly men with a metastatic lung, digestive or cutaneous cancer. Analyses showed that dermatological symptoms in 22 patients were associated for a majority of them with a decrease of quality of life, characterized by difficulties in houseworks and leisure activities, and a social functioning impairment. Adverse skin events did not seem to affect emotional state. These results must be confirmed by further investigations in a larger-scale prospective research.